Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)

Benedetto Vitiello, Howard B. Abikoff, Shirley Z. Chuang, Scott H. Kollins, James T. McCracken, Mark A. Riddle, James M. Swanson, Tim Wigal, James J. McGough, Jaswinder K. Ghuman, Sharon B. Wigal, Anne M. Skrobala, Mark Davies, Kelly Posner, Charles Cunningham, Laurence L. Greenhill

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to examine immediate-release methylphenidate effectiveness during the 10-month open-label continuation phase of the Preschoolers with attention-deficit/hyperactivity disorder (ADHD) Treatment Study (PATS). Methods: One hundred and forty preschoolers with ADHD, who had improved with acute immediate-release methylphenidate (IR-MPH) treatment, entered a 10-month, open-label medication maintenance at six sites. Assessments included the Clinical Global Impression-Severity (CGI-S), CGI-Improvement (CGI-I), Children's Global Assessment Scale (C-GAS), Swanson, Nolan, and Pelham Questionnaire (SNAP), Scale Strengths and Weaknesses of ADHD-Symptoms and Normal Behaviors (SWAN), Social Competence Scale, Social Skills Rating System (SSRS), and Parenting Stress Index-Short Form (PSI-SF). Results: For the 95 children who completed the 10-month treatment, improvement occurred on the CGI-S (p = 0.02), CGI-I (p < 0.01), C-GAS (p = 0.001), and SSRS (p = 0.01). SNAP and SWAN scores remained stable. Forty five children discontinued: 7 for adverse effects, 7 for behavior worsening, 7 for switching to long-acting stimulants, 3 for inadequate benefit, and 21 for other reasons. The mean MPH dose increased from 14.04 mg/day ± SD 7.57 (0.71 ± 0.38 mg/kg per day) at month 1 to 19.98 mg/day ± 9.56 (0.92 ± 0.40 mg/kg per day) at month 10. Conclusions: With careful monitoring and gradual medication dose increase, most preschoolers with ADHD maintained improvement during long-term IR-MPH treatment. There was substantial variability in effective and tolerated dosing.

Original languageEnglish (US)
Pages (from-to)593-603
Number of pages11
JournalJournal of child and adolescent psychopharmacology
Volume17
Issue number5
DOIs
StatePublished - Nov 1 2007

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS)'. Together they form a unique fingerprint.

  • Cite this

    Vitiello, B., Abikoff, H. B., Chuang, S. Z., Kollins, S. H., McCracken, J. T., Riddle, M. A., Swanson, J. M., Wigal, T., McGough, J. J., Ghuman, J. K., Wigal, S. B., Skrobala, A. M., Davies, M., Posner, K., Cunningham, C., & Greenhill, L. L. (2007). Effectiveness of methylphenidate in the 10-month continuation phase of the Preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). Journal of child and adolescent psychopharmacology, 17(5), 593-603. https://doi.org/10.1089/cap.2007.0058